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Abstract Acute lymphoblastic leukemia is the most
prevalent cancer in children. Novel components to help
struggle aggressive malignancies and overcome some side
effects of conventional treatments could be a promising
strategy. Epigallocatechingallate (EGCG), have attracted
the attention of scientists for prevention or treatment of
some cancers. Jurkat cells were incubated with the different
concentrations of EGCG (30–100 lm) for 24, 48, and 72 h
and cell viability was investigated using MTS test. Apop-
tosis and the level of caspase 3 alterations were evaluated
using flowcytometry and expression of Fas by Real Time
PCR. EGCG decreased viability of cells with an inhibition
concentration (IC50) of 82.8 ± 3.1, 68.8 ± 4 and
59.7 ± 4.8 lM in 24,48 and 72 h. 50, 70 and 100 lM
concentrations of EGCG induced apoptosis in about 31, 40
and 71% of the cells, respectively. The mean value of
caspase 3 positive cells in the presence of 50, 70 and
100 lm concentrations of EGCG was 19.3 ± 2.9,
29.5 ± 3.1 and 61.2 ± 3.4 respectively compared to
7.8 ± 1.1 in control with a significant difference at 100 lm
concentration. Treatment with EGCG for 48 h enhanced
the expression of Fas reaching to a significant level at
100 lM concentration. EGCG is effective in decrease cell
viability, apoptosis induction and enhancement of caspase
3 and Fas expression level in jurkat cells. A comprehensive
understanding of molecular events and pharmacokinetics
of the component and experiments in animal models are
required for dose determination and its interaction with
other components of combination chemotherapy.
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Introduction
Cancer is one of the most prevalent causes of death and is
expected to increase from 14.1 million new cases in 2012
to 24 million in 2035 and the most rises will be in devel-
oping countries [1]. Acute lymphoblastic leukemia is the
most prevalent cancer in children with different incidence
according to ethnic and race reaching to about 40 per
million in whites [2]. Acute leukemia is an aggressive
disease and there is a serious need for novel components to
help struggle these malignancies. A promising strategy for
cancer prevention is introducing drugs that block the
development of cancer. Natural compounds and their
derivatives have influenced blood cells and components
and have been considered for the treatment of different
diseases including cancer [3, 4]. Some extracts of medici-
nal plants have been used to overcome multidrug resistance
[5]. Epigallocatechin-3-gallate (EGCG), a polyphenolic
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compound, is the most important catechin derived from
green tea with anticancer properties against many cancer
cell lines [6]. EGCG has been found to comprise about
30% of anti-oxidant capacity of green tea and effectively
diminishes cellular injury by reducing free radicals causing
oxidative damage [7, 8]. Many studies have demonstrated
the anti-oxidant activity of polyphenols in different cells
and tissues. Studies have shown that EGCG induces
in vitro apoptosis in some cell lines. It has also been
demonstrated that EGCG incorporate into the lipid bilayer
of the membrane and influence multiple signaling path-
ways [9]. A key regulator of apoptosis is Fas/Fas ligand
system which is one of the major extrinsic apoptosis
pathways for T cells. Many plant derivatives have shown
their anti-cancer effects on T cell leukemia cell lines, as we
have reported increasing apoptosis of this cell line with
pterostilbene [10]. EGCG causes cell cycle arrest through
regulation of expression of regulatory proteins and inhibi-
tion of NFjB activation [11]. Moreover EGCG increases
IL23-related DNA repair and activate cytotoxic T cells in
tumor. This polyphenolic compound has shown anti-pro-
liferative effects on drug sensitive and resistance small cell
lung carcinoma [12]. Differentiated promyelocytic cells
have been resistant to EGCG, whereas HL-60 undifferen-
tiated leukemia cells were sensitive in Okada et al. study
which is a favorable chemo-therapeutic effect [13]. EGCG
is effective on some of the biological pathways such as
growth factor signaling, kinase dependent mitogen acti-
vated protein and ubiquitin/proteasome pathways [14]. In B
cell chronic lymphocytic leukemia, EGCG has increased
apoptosis accompanied by caspase-3 activation [15]. On
the other hand it can inhibit angiogenesis in some tumors.
In the present work, we reported the effect of EGCG on
apoptosis through the Fas pathway on a T lymphoblastic
leukemia cell line.
Materials and Methods
Cell Culture
Jurkat cells (Pasteur Institute, Iran) were grown in RPMI-
1640 culture medium supplemented with 10% fetal calf
serum, 0.3 mg/ml glutamine, 100 IU penicillin and
100 lg/ml streptomycin, and kept in a humidified atmo-
sphere containing 5% CO2 at 37. Cells in the exponential
phase were used for all experiments. Cell count was per-
formed by hemocytometer and tripane blue dye.
Analysis of Cell Viability
MTS was used to evaluate cell viability according to
Thabrew method [16]. Briefly, Cells at 1 9 104 cells/ml
were cultured in a 96-well tissue culture plate and incu-
bated for 24 h. The cells then were treated with different
concentrations of EGCG (0–100 lM) for 24, 48 and 72 h
in above culture media. MTS was added to each well and
cells were incubated for 3 h more at 37 C in a dark place.
The optical density (OD) against the background (culture
medium with DMSO) at 490 nm was assessed using
ELISA reader (stat fax-2100 awarenes). Each independent
experiment was repeated at least three times and the con-
centration required for a 50% inhibition of growth (IC50)
was determined. The OD is relative to the total number of
living cells. Normal PBMC was tested along with cell line
at the same experimental conditions.
Flowcytometric Analysis of Apoptosis
Apoptosis was detected by flow cytometry with the FITC
Annexin V Apoptosis Detection Kit (BD Pharmingen).
Briefly, jurkat cells were seeded in a 6 well plate in com-
plete media for 24 h. The cells then treated with different
concentrations of EGCG for 48 h, were afterward har-
vested and washed in PBS twice. 106 cells were re-sus-
pended in 1 ml 19 binding buffer. 105 cells were incubated
with 5 ll of FITC-labeled annexin V and PI (propidium
iodide) at room temperature in darkness for 20 min, then
400 ll of 19 binding buffer were added. The tube was
mixed gently, and kept on ice and analyzed by flow
cytometry (PARTEC, Germany). FITC positive cells are
apoptotic and could be at first or in final stage of apoptosis.
Both populations were recorded as apoptotic cells.
Untreated sample was considered as negative control for
comparison.
Real Time PCR for Fas Expression
Cells were treated with different concentrations of EGCG
or left untreated for 48 h, then harvested. Total RNA was
extracted using RNA extraction Biozol method (Bioflux,
Japan). Total RNA concentration was determined using
Thermo Scientific nanodrop 2000, USA. The extracted
RNA was re-suspended in DEPS water and stored at
-70 C for future use. cDNA was synthesized using ran-
dom hexamers and oligo dt primers according to the
manufacturer recommendation (Revert Aid first cDNA
synthesis Kit, Thermo Scientific, Finland). An aliquot of
the resulting DNA was used for PCR amplification
according to previously described method using specific
primers to achieve optimal thermal and concentration
conditions (Thermocycler ASTEC, PC818, Japan). The
amplified PCR products was then analyzed by polyacry-
lamide gel electrophoresis. Fas and b-actin primers were
designed using the Gene Works Sofware Program. Thermal
cycling conditions are summarized in Table 1. To evaluate
Indian J Hematol Blood Transfus
123
the expression of Fas, quantitative PCR was performed and
optimized to an amplification efficiency of more than 95%,
Rotor Gene RG 3000 Corbet Research, Australia. The
primer sets amplified Fas and b-actin to 174 and 118 bp
respectively. Table 2 demonstrates the primers and Taq-
Man probe sequences. The system generates a real time
amplification plot based on the normalized fluorescence
signal. The comparative cycle (ct) value of target gene was
normalized by subtracting the ct value of b-actin (Dct). The
Dct value was used to calculate the relative expression
level of Fas to b-actin [17].
Detection of Caspase 3 Positive Cells
Cells were incubated with different concentrations of
EGCG and activated-caspase 3 positive cells were identi-
fied using intracellular staining and flowcytometry
according to the described method (BD). Briefly, the cells
were cultured in a 6-well plate at a concentration of
200,000 cells/well in 2 ml complete media and treated with
different concentrations of EGCG for 48 h. The cells were
washed and re-suspended in cytofix/cytoperm solution and
incubated for 20 min on ice. The cells were washed again
with perm/wash buffer and incubated with PE conjugated
anti-caspase 3 in a perm/wash buffer suspension at room
temperature for 30 min in darkness. After the final wash,
the cells were re-suspended in perm/wash buffer and pre-
pared for flowcytometric analysis.
Statistical Analysis
Data were presented as mean ± SD and analyzed by SPSS,
version 18, using Kruskal–Wallis and Dunn’s Multiple
comparison test. The difference between control and each
concentration considered significant if p value\0.05. All
experiments were repeated at least 3 independent times.
Probit analysis was used for IC50 calculation and Graph-
Pad prizm for Graphs.
Results
EGCG Decreased Cell Viability in a Time-
and Dose-Dependent Behavior
Jurkat cells and PBMC were incubated with various con-
centrations of EGCG for 24, 48 and 72 h. Decrease of cell
viability was observed after incubation time in a dose- and
time-dependent behavior (Fig. 1). Jurkat cell viability was
about 91, 76, 71%, at a concentration of 30 lM after 24, 48
and 72 h respectively, however viability declined to 37, 22
and 16% at a concentration of 100 lM after above incu-
bation periods. Inhibition concentration (IC50) was
82.82 ± 3.12 lM in 24 h, 68.84 ± 4.03 lM in 48 h and
59.7 ± 4.85 lM in 72 h. Cell viability of normal PBMC
did not reach to IC50 as at the highest used concentration,
100 lM, it was still about 65% after 48 h incubation time.
EGCG Increased Apoptosis of Lymphoblastic
Leukemia Cells
The apoptosis was determined by a double staining method
with Annexin V-FITC/PI. Jurkat cells were incubated with
various concentrations (0, 50, 70, 100 lM) of EGCG for
48 h. Apoptosis was increased after treatment with differ-
ent concentrations of the drug compared to control group.
Figure 2a shows an example of the apoptosis in the pres-
ence of 50 and 70 lM concentration of ECGC. Figure 2b
demonstrates the values of 3 independent experiments. 50,
70 and 100 lM concentrations of EGCG induced apoptosis
in about 31, 40 and 71% of the cells, respectively.
EGCG Enhanced Fas Expression in Jurkat Cells
Cells treated with different concentrations of EGCG.
Standard curve in this reaction was established with 5
concentration solutions. Expression levels of b-actin in
each solution were analyzed and the expression level of Fas
was also detected in the same reaction system. All exper-
iments were performed by three repeats. Fas was expressed
at baseline level in untreated cells. Treatment with EGCG
enhanced the expression of Fas reaching to a significant
level at 100 lM concentration of EGCG. The expression
Table 1 Thermal cycling condition of Fas/b-actin
95 C for 10 min
45 cycle of 95 C for 15 s, 60 C for 60 s
Table 2 Primer and probe
sequences
Gene Primer and probe sequences Product size (bp)
b-Actin F 50 AGCCTCGCCTTTGCCGA 30 147
R 50 CTGGTGCCTGGGGCG 30
Probe FAM CCGCCGCCCGTCCACACCCGCC TAMRA
Fas F 50 TGAAGGACATGGCTTAGAAGTG 30 118
R 50 GGTGCAAGGGTCACAGTGTT 30
Probe FAM AAACTGCACCCGGACCCAGAATACC TAMRA
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was about 3 times at 70 lM and more than 3 times at
100 lM concentration of EGCG. Treatment with concen-
trations of more than 100 lM did not exhibit profound Fas
expression as there was a massive cell death at higher
concentrations. No significant difference was observed
among different concentrations (Fig. 3).
EGCG Increased Caspase 3 Positive Cells
Caspase 3 positive cells were detected by intracellular
staining and flowcytometry after the cells were perme-
ablized, fixed and incubated with anti-caspase 3 PE-con-
jugated monoclonal antibody. The percentage of positive
cells was detected by flowcytometry after 48 h incubation
with different concentration of EGCG. Figure 4a demon-
strates an example of flowcytometric analysis of caspase-3.
The mean value of positive cells in three independent
experiments in the presence of 50, 70 and 100 lm con-
centrations of EGCG were compared to control. As shown
in Fig. 4b, the mean was 19.3 ± 2.9, 29.5 ± 3.1 and
61.2 ± 3.4 respectively compared to 7.8 ± 1.1 in control.
The ratio of positive cells increased in all used concen-
trations compared to control, but the difference was only
significant at 100 lm concentration (Fig. 4b).
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Fig. 1 Effect of different concentrations of EGCG on viability of
Jurkat cell line after 24, 48, and 72 h. Decreased cell viability is time
and dose dependent
A
70µM50µMControl
EGCG concentration
B
co
ntr
ol 50 70 10
0
0
20
40
60
80 *
P=0.016
Concentration ( M)
Ap
op
to
si
s (
%
)
µ
Fig. 2 Analysis of apoptosis by
flowcytometry. Jurkat cells were
treated with EGCG for 48 h and
compared to control. a The level
of apoptosis was 8.2, 26 and
34% in control, 50 and 70 lM
concentrations of EGCG
respectively. b The mean value
of apoptosis of 3 independent
experiments. The effect of
different concentrations of
EGCG on Jurkat cell apoptosis
after 48 h incubation compared
to control group. A significant
difference was observed in the
level of apoptosis between
control and the cells treated with
100 lM concentration of EGCG
(*a significant difference)
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Discussion
The treatment of cancer including leukemia has encoun-
tered considerable changes in recent years. New cytotoxic
drugs improved the outcome of the patients, but side
effects are still the main concern. Polyphenolic compounds
of green tea have attracted wide range of researches in
recent years and some studies have reported improve of
prognosis of some cancers including low grade B cell
lymphoma with green tea [18]. Anti-proliferative effect of
EGCG through induction of apoptosis has been already
reported in some cell lines [19] with variable IC50 based
on the cell types. While it has been a potent anti-prolifer-
ative agent with an IC50 as low as 4.9 lM in SPC-A-1
human lung carcinoma cell line at 48 h incubation time,
others reported moderate effects on proliferation of human
retinal pigment epithelial cells [20, 21]. The anti-prolifer-
ative effect of EGCG has also been demonstrated on mice
spleen cells at concentrations of 2.5–10 lM [22]. In the
latter study Li W et al. found cell cycle arrest at G0/G1
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Fig. 3 Effect of EGCG on Fas expression. Jurkat cells were treated
with different concentrations of EGCG or left untreated. The Fas
expression was more than control at all used concentrations, but the
difference was only significant between control and 100 lM
concentration
Fig. 4 Effect of EGCG on the level of caspase 3 positive cells. Jurkat
cells were incubated with EGCG for 48 h and caspase 3 positive cells
were detected by intracellular staining and flowcytometry. a An
example of flowcytometric analysis of caspase 3 positive cells. The
level of positive cells increased with increasing concentration. b The
mean value of positive cells in the presence of 50, 70 and 100 lM
concentration of EGCG compared to control. The difference reached
to a significant level at 100 lM concentration of EGCG (**). The
demonstrated values are the mean of 3 independent experiments
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rather than increased apoptosis. In hepatocellular carci-
noma cell lines cell growth has been inhibited at concen-
tration of 50–100 lM [23]. Since T-ALL has been known
as a poor prognosis leukemia we focused of a T lym-
phoblastic leukemia. Here we demonstrated the decrease of
jurkat cell viability with a time and dose dependent manner
in the presence of EGCG as we had an IC50 about 70 lM
at 48 h and about 60 at 72 h. At a specific time point, the
viability decreased parallel to increasing the concentration.
Meanwhile we demonstrated less toxic effects on normal
PBMC upon EGCG treatment.
The dose dependency is in agreement with Rao and
Pagidas in human ovarian cancer cells [24]. Our data
showed decrease of cell viability in 24 h as well, starting at
20 lM concentration which is different than that found in
pancreatic cell line with 20 and 40 lM concentrations [25].
This finding confirms the difference between different
cancer cells and possibly different experimental conditions.
Induction of apoptosis is one of the main approaches in
anti-cancer therapy. The present study shows the
enhancement of apoptosis in a T cell line with a dose
dependent behavior. A concentration of the drug which was
associated with more apoptosis also caused more prolifer-
ation inhibition in cell viability assay. Green tea catechins
are susceptible to autoxidation and accumulates as H2O2
and may influence apoptosis [26]. EGCG has inhibited
cycxloxigenase-2 expression in 10–100 lM concentrations
in androgen sensitive and insensitive prostatic carcinoma
cell lines [14]. Berletch et al. studied the effect of EGCG
on MCF-7 breast cancer and HL-60 leukemia cell lines.
They found the apoptosis rate at day 9 two times of the
control in HL-60 treated cells, however it was more than 11
times in MCF-7 cells. They also found the difference in
down regulation of hTERT mRNA between these two cell
types [27]. Different sensitivity of the cells to apoptosis
may indicate that different mechanisms can be involved in
different cell lines. It seems that the diminution of viability
in the presence of EGCG in the present work was depen-
dent on the level of apoptosis (vs. necrosis), which is an
advantage of anti-cancer treatments.
Fas is a chief extrinsic pathway of apoptosis in T cells.
Alteration of some signaling pathways have already been
reported and some researchers believe that EGCG by non-
specific binds causes protein precipitation [28]. While
some studies have indicated the anti-oxidant activity of
green tea, others have noticed the hydrogen peroxide pro-
duction as the main cause of cytotoxic effects. Catalase
addition to cell culture has shown to reverse that anti-
proliferative effect [29]. EGCG has reported to inhibit
proteasome activity in some cancer cells and control the
growth of tumor by causing cell cycle arrest at G1. Human
normal fibroblasts are not sensitive to this effect [30]. We
found enhancement of apoptosis and Fas expression in this
T cell leukemia line in the presence of EGCG. This effect
has already been found in some other cancer cell lines.
Irimie et al. [31] have found the activation of Fas expres-
sion in oral carcinoma cells and Wang et al. [32] have
revealed the up regulation of Fas and BAX and down
regulation of Bcl2. The similar results for the Fas expres-
sion have been reported in head and neck squamous cell
carcinoma and human breast cancer cells [33, 34]. All of
the above findings suggest the Fas/Fas ligand pathway as a
mechanism for apoptosis with EGCG. Our findings showed
dose-dependency of Fas expression as we had more
expression with higher concentrations. The data of caspase-
3 detection as the nearly the end-point of this pathway also
showed enhancement in the presence of EGCG.
Caspase 3 positive cells were increased in all used
concentrations and reached to a significant level at 100 lM
concentration of EGCG which is consistent with our data
of Fas expression. This finding is in agreement with some
other reported cell lines. In rat hepatocytes, caspase 3
activity has been reported to increase in cell lysate after
exposure to EGCG in Kucera et al. study [25]. A derivative
of EGCG, EGCG-MP, increased the expression of caspase-
3 in K562, a promyelocytic leukemia cell line which is in
agreement with our data in jurkat cells [35]. The similar
results have also been reported in pancreatic and
nasopharyngeal cell lines [25, 36].
Overall, we represented that EGCG induces apoptotic
effects on a T-cell lymphoblastic line based on the con-
centration of the drug. This effect is apparently through the
apoptosis, but the exact mechanism of EGCG induced
apoptosis or cell death is still in question. Since EGCG had
minimal toxic effect on normal cells in vitro, it could be
considered as a part of combination therapy for ALL to
enhance the anti-cancer effect of chemotherapy after
in vivo approval in experimental models. More over such a
component may allow reducing the dose of chemotherapy
agents to exert less cytotoxicity and side effects as we have
recently reported the synergistic effect of thymoquinone in
combination with doxorubicin (DoX) on T-cell lym-
phoblastic leukemia cells (jurkat) [37].
Conclusion
In the present work, we provided evidence of the induction
of apoptosis through the Fas/Fas ligand activation, however
other apoptosis mechanisms may be involved upon EGCG
treatment in T cell line which need to be investigated. As
EGCG had inhibitory effect on T cell growth, autoimmune
diseases can also be a target for future studies. The
understanding of molecular events will provide more
insights to the development of new therapeutic agents.
However more in-depth in vitro experiments are needed
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with the lymphoblasts of ALL patients and then in vivo
studies in animal models. A comprehensive understanding
of pharmacokinetics of the component is required for dose
determination and its interaction with other components of
combination chemotherapy.
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